Top Markets
#1 Fake World Assets Fake World Assets +10.69%
#2 B3 (Base) B3 (Base) +10.34%
#3 Janction Janction +9.46%
#4 Verus Coin Verus Coin +7.95%
#5 TENDIES TENDIES +6.38%
#6 GoPlus Security GoPlus Security +4.67%
#7 龙虾 (Lobster) 龙虾 (Lobster) +4.03%
#8 Provenance Blockchain Provenance Blockchain +3.76%
#9 Everything Everything +3.72%
#10 OVERTAKE OVERTAKE +3.30%
Coin of the day
Fake World Assets Fake World Assets
Settings
Language
ENGLISH
Currency
USD
Theme
Kineta, Inc. Kineta, Inc.

Kineta, Inc.

KA
Rank in Stocks #34153
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing... Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Share Price
$0.617
Last synced: 2024-10-14
Market Cap
$6.13M
Change (1 day)
0.49%
Change (1 year)
0.00%
Country
US
Trade Kineta, Inc. (KA)

Category

Healthcare
P/E ratio for Kineta, Inc. (KA)
P/E ratio as of August 2026 TTM: -0.40
According to Kineta, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.40. At the end of 2023 the company had a P/E ratio of -2.85.
P/E ratio history for Kineta, Inc. from 2015 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.40 -8.05%
2024 -0.44 -84.69%
2023 -2.85 473.79%
2022 -0.50 -74.88%
2021 -1.97 -11.75%
2020 -2.24 46.24%
2019 -1.53 -2.24%
2018 -1.57 -19.07%
2017 -1.93 -59.65%
2016 -4.79 -6.41%
2015 -5.12 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -7,317.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -7,667.77%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -4,643.01%
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.